Athersys Inc. (ATHX)

Name: Athersys Inc. (ATHX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Athersys Inc. (ATHX)

Stock Card

$0.01

$-0.02 (-72.34%)

As on 11-Mar-2024 09:30EDT

Market cap

$1 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

219.6

Div. Yield

0 %

Athersys (ATHX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.01 High: 0.01

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-39 Mln
ROE

-12.8 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.4
Debt to Equity

0
Book Value

$--
EPS

$-2.3
Face value

--
Shares outstanding

61,718,800

10 Years Aggregate

CFO

$-346.48 Mln

EBITDA

$-410.57 Mln

Net Profit

$-426.24 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Athersys (ATHX)	--	--	-72.3	-99.6	-94.9	-82.3	-61.5
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 11-Mar-2024 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2021	2020	2019	2018	2017	2016	2015
Athersys (ATHX)	-48.6	42.3	-14.6	-20.3	18.3	48.5	-34.8
S&P Small-Cap 600	25.3	9.6	20.9	-9.7	11.7	24.7	-3.4
BSE Sensex	22.0	15.8	14.4	5.9	27.9	1.9	-5.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Athersys (ATHX)	0.0	0.8	0.1	-42.1	-30,412.4	--	--	219.6
AcelRx Pharmaceuticals (ACRX)	1.1	14.6	0.7	-10.3	-1,089.9	-57.3	--	0.7

Shareholding Pattern

View Details

About Athersys (ATHX)

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases,... inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio. Read more

CEO, Sec., Principal Accounting Officer & Director

Mr. Daniel A. Camardo M.B.A.
CEO, Sec., Principal Accounting Officer & Director

Mr. Daniel A. Camardo M.B.A.
Headquarters

Cleveland, OH
Website

https://www.athersys.com

FAQs for Athersys (ATHX)

What is the current share price of Athersys Inc (ATHX) Today?

The share price of Athersys Inc (ATHX) is $0.01 (NASDAQ) as of 11-Mar-2024 09:30 EDT. Athersys Inc (ATHX) has given a return of -94.86% in the last 3 years.

What is the current PB & PE ratio of Athersys Inc (ATHX)?

Since, TTM earnings of Athersys Inc (ATHX) is negative, P/E ratio is not available.
The P/B ratio of Athersys Inc (ATHX) is 219.57 times as on 11-Mar-2024, a 4004 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.